Hematologic Toxicities in Colorectal Cancer Patients who Received FOLFOX4 (original) (raw)

Folfox 2 Regimen in Heavily Pretreated Patients with Advanced Colorectal Cancer

Tumori Journal, 2002

Safe Use of FOLFOX in Two Patients With Metastatic Colorectal Carcinoma and Severe Hepatic Dysfunction

Clinical Colorectal Cancer, 2011

Safety Analysis of FOLFOX4 Treatment in Colorectal Cancer Patients: A Comparison Between Two Asian Studies and Four Western Studies

Silvano Brienza

Clinical Colorectal Cancer, 2012

View PDFchevron_right

FOLFOX in patients aged between 76 and 80 years with metastatic colorectal cancer

Arie Figer

Cancer, 2007

View PDFchevron_right

Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia …

Sante ROMITO

Journal of clinical …, 2005

View PDFchevron_right

Impact of CAPOX or FOLFOX4 on Spleen size, Platelet Count and Liver Function when Partnered Cetuximab as First-line Treatment for KRAS Wild-type Metastatic Colorectal Cancer

Rico Liu

Cancer Research Frontiers, 2015

View PDFchevron_right

FOLFOX Alternated with FOLFIRI as First-Line Chemotherapy for Metastatic Colorectal Cancer

Jorge Aparicio

Clinical Colorectal Cancer, 2005

View PDFchevron_right

Anemia and thrombocytopenia in patients undergoing chemotherapy for solid tumors: A descriptive study of a large outpatient oncology practice database, 2000–2007

suresh aravind

Clinical Therapeutics, 2009

View PDFchevron_right

Predictive factors for chemotherapy-related toxic effects in patients with colorectal cancer

Daniele Santini

Nature Clinical Practice Oncology, 2008

View PDFchevron_right

Folfox4 in Advanced Colorectal Cancer: A Monoinstitutional Experience

silvio monfardini

Tumori Journal, 2006

View PDFchevron_right

Results of Adjuvant FOLFOX Regimens in Stage III Colorectal Cancer Patients: Retrospective Analysis of 667 Patients

Veli Berk

Oncology, 2013

View PDFchevron_right

FOLFOX4 in the treatment of metastatic colorectal cancer in elderly patients: A prospective study

Umberto Tirelli

Archives of Gerontology and Geriatrics, 2011

View PDFchevron_right

Modification of leucovorin dose within a simplified FOLFOX regimen improves tolerability without compromising efficacy

David Goldstein

Clinical colorectal cancer, 2007

View PDFchevron_right

Efficacy and Safety of Xelox in Comparison with Folfox in Metastatic Colorectal Cancer

Reeta Kumari

Pakistan Journal of Medical and Health Sciences

View PDFchevron_right

The role of haemoglobin level in predicting the response to first-line chemotherapy in advanced colorectal cancer patients

Levy Brizzy

British Journal of Cancer, 2006

View PDFchevron_right

Phase III Trial of Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) Compared With Infusional Fluorouracil, Leucovorin, and Irinotecan (FOLFIRI) As First-Line Treatment for Metastatic Colorectal Cancer: The Gruppo Oncologico Nord Ovest

Vincenzo Picone

Journal of Clinical Oncology, 2007

View PDFchevron_right

ASSESSMENT of HEMATOLOGICAL PARAMETERS BEFORE and AFTER ADJUVANT CHEMOTHERAPY in PATIENTS with COLORECTAL CANCER

Benan Kasapoglu

Acta Oncologica Turcica, 2019

View PDFchevron_right

Haematologic Parameters in Metastatic Colorectal Cancer Patients Treated with Capecitabine Combination Therapy

Oktay Bozkurt

Asian Pacific Journal of Cancer Prevention, 2014

View PDFchevron_right

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer

Michel Ducreux

International Journal of Cancer, 2011

View PDFchevron_right

A Comparative Study of Treatment Toxicities Between FOLFOX 4 and Modified FOLFOX 6 in Iranian Colorectal Cancer Patients

Amir Shahram Yousefi Kashi

Iranian Journal of Cancer Prevention, 2017

View PDFchevron_right

Phase III Randomized Trial of FOLFIRI Versus FOLFOX4 in the Treatment of Advanced Colorectal Cancer: A Multicenter Study of the Gruppo Oncologico Dell'Italia Meridionale

Francesco Carrozza

Journal of Clinical Oncology, 2005

View PDFchevron_right

Thrombotic events in metastatic colorectal cancer patients treated with leucovorin, fluorouracil and irinotican (FOLFIRI) plus bevacizumab

Hua Shen

View PDFchevron_right

Correlation of pretreatment hemoglobin and platelet counts with clinicopathological features in colorectal cancer in Saudi population

alaa alanazi

Saudi Journal of Gastroenterology, 2014

View PDFchevron_right

Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study

Miguel Navarro

Annals of Oncology, 2008

View PDFchevron_right

A randomized phase II study to compare oxaliplatin plus 5-fluorouracil and leucovorin (FOLFOX4) versus oxaliplatin plus raltitrexed (TOMOX) as first-line chemotherapy for advanced colorectal cancer

Eduardo Garcia-Rico

Clinical and Translational Oncology, 2012

View PDFchevron_right

Phase I Trial of Oxaliplatin, Infusional 5-Fluorouracil, and Leucovorin (FOLFOX4) With Erlotinib and Bevacizumab in Colorectal Cancer

Michael Carducci

Clinical Colorectal Cancer, 2010

View PDFchevron_right

Hematologic Toxicities in Colorectal Cancer Patients who Received FOLFOX4 (original) (raw)

Related papers